[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2004001079A1 - Compuestos derivados de pirrol condensados, inhibidores del factor xa y/o del factor vlla; composicion farmaceutica; proceso de preparacion; y su uso para tratar fibrinolisis, la formacion anormal de trombos, infarto o miocardio agudo, trastornos car - Google Patents

Compuestos derivados de pirrol condensados, inhibidores del factor xa y/o del factor vlla; composicion farmaceutica; proceso de preparacion; y su uso para tratar fibrinolisis, la formacion anormal de trombos, infarto o miocardio agudo, trastornos car

Info

Publication number
CL2004001079A1
CL2004001079A1 CL200401079A CL2004001079A CL2004001079A1 CL 2004001079 A1 CL2004001079 A1 CL 2004001079A1 CL 200401079 A CL200401079 A CL 200401079A CL 2004001079 A CL2004001079 A CL 2004001079A CL 2004001079 A1 CL2004001079 A1 CL 2004001079A1
Authority
CL
Chile
Prior art keywords
factor
thrombes
fibrinolisis
infarto
pirrol
Prior art date
Application number
CL200401079A
Other languages
English (en)
Inventor
Marc Nazare
Volkmar Wehner
Kurt Ritter
Hans Matter
David William Will
Matthias Urmann
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of CL2004001079A1 publication Critical patent/CL2004001079A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL200401079A 2003-05-19 2004-05-17 Compuestos derivados de pirrol condensados, inhibidores del factor xa y/o del factor vlla; composicion farmaceutica; proceso de preparacion; y su uso para tratar fibrinolisis, la formacion anormal de trombos, infarto o miocardio agudo, trastornos car CL2004001079A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03011304A EP1479680A1 (en) 2003-05-19 2003-05-19 Azaindole derivatives as Factor Xa inhibitors

Publications (1)

Publication Number Publication Date
CL2004001079A1 true CL2004001079A1 (es) 2005-04-08

Family

ID=33040951

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200401079A CL2004001079A1 (es) 2003-05-19 2004-05-17 Compuestos derivados de pirrol condensados, inhibidores del factor xa y/o del factor vlla; composicion farmaceutica; proceso de preparacion; y su uso para tratar fibrinolisis, la formacion anormal de trombos, infarto o miocardio agudo, trastornos car

Country Status (25)

Country Link
EP (2) EP1479680A1 (es)
JP (1) JP4733642B2 (es)
KR (1) KR20060012636A (es)
CN (1) CN100347172C (es)
AR (1) AR045682A1 (es)
AU (1) AU2004238500B2 (es)
BR (1) BRPI0410429A (es)
CA (1) CA2526084A1 (es)
CL (1) CL2004001079A1 (es)
CR (1) CR8088A (es)
EC (1) ECSP056179A (es)
HK (1) HK1089175A1 (es)
MA (1) MA27799A1 (es)
MX (1) MXPA05012156A (es)
NO (1) NO20055911L (es)
NZ (1) NZ543669A (es)
OA (1) OA13169A (es)
PE (1) PE20050554A1 (es)
RS (1) RS20050857A (es)
RU (1) RU2330853C2 (es)
TN (1) TNSN05296A1 (es)
TW (1) TW200510411A (es)
UA (1) UA86767C2 (es)
WO (1) WO2004101563A1 (es)
ZA (1) ZA200508150B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006017741D1 (de) * 2005-11-18 2010-12-02 Hoffmann La Roche Azaindol-2-carboxamid-derivate
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
BR112015003098A2 (pt) 2012-08-17 2017-08-22 Bayer Cropscience Ag Azaindolecarboxamidas e azaindoletiocarboxamidas como inseticidas e acaricidas.
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN111834531B (zh) * 2019-04-15 2022-04-19 天津大学 一种有机半导体材料、制备方法及应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1241472B (it) 1990-07-06 1994-01-17 Olivier Linda Dispositivo elettromeccanico per la cattura continua in particolare di topi e ratti.
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
CZ296439B6 (cs) 1994-04-26 2006-03-15 Selectide Corporation Inhibitory faktoru Xa
IL135536A0 (en) * 1997-12-19 2001-05-20 Schering Ag Ortho-anthranilamide derivatives and pharmaceutical compositions containing the same
CA2316172C (en) * 1997-12-24 2010-02-02 Aventis Pharma Deutschland Gmbh Indole derivatives as inhibitors of factor xa
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
JP4241970B2 (ja) * 1998-10-30 2009-03-18 中外製薬株式会社 アミド結合を有するインドール誘導体、及びモノ又はジアザインドール誘導体
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
CN1272316C (zh) * 1999-09-17 2006-08-30 千禧药品公司 苯甲酰胺和相关的因子Xa抑制剂
JP2001294572A (ja) * 2000-02-09 2001-10-23 Dai Ichi Seiyaku Co Ltd 新規スルホニル誘導体
US6436965B1 (en) * 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
AU2001273040A1 (en) * 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
JP2004529113A (ja) * 2001-03-07 2004-09-24 ファイザー・プロダクツ・インク ケモカイン受容体活性のモジュレーター
AU2002303264A1 (en) * 2001-04-09 2002-10-21 Bristol-Myers Squibb Company Fused heterocyclic inhibitors of factor xa
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
WO2003053361A2 (en) * 2001-12-20 2003-07-03 Osi Pharmaceuticals, Inc. PYRROLOPYRIMIDINE A2b SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE
DE10214832A1 (de) * 2002-04-04 2003-10-16 Merck Patent Gmbh Phenylderivate 4
JP2004203791A (ja) * 2002-12-25 2004-07-22 Dai Ichi Seiyaku Co Ltd 芳香族化合物
JP2004210716A (ja) * 2002-12-27 2004-07-29 Dai Ichi Seiyaku Co Ltd ジアミド誘導体
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors

Also Published As

Publication number Publication date
ZA200508150B (en) 2007-02-28
BRPI0410429A (pt) 2006-06-06
MXPA05012156A (es) 2006-08-18
NO20055911L (no) 2006-02-10
WO2004101563A1 (en) 2004-11-25
AU2004238500A1 (en) 2004-11-25
RS20050857A (en) 2007-11-15
CN1791601A (zh) 2006-06-21
RU2330853C2 (ru) 2008-08-10
CN100347172C (zh) 2007-11-07
PE20050554A1 (es) 2005-08-04
RU2005139557A (ru) 2007-06-27
OA13169A (en) 2006-12-13
HK1089175A1 (en) 2006-11-24
TNSN05296A1 (en) 2007-07-10
CA2526084A1 (en) 2004-11-25
UA86767C2 (ru) 2009-05-25
EP1636226B1 (en) 2014-10-15
AU2004238500B2 (en) 2010-07-22
JP4733642B2 (ja) 2011-07-27
CR8088A (es) 2006-09-22
KR20060012636A (ko) 2006-02-08
NZ543669A (en) 2008-12-24
TW200510411A (en) 2005-03-16
MA27799A1 (fr) 2006-03-01
AR045682A1 (es) 2005-11-09
JP2006528214A (ja) 2006-12-14
EP1479680A1 (en) 2004-11-24
ECSP056179A (es) 2006-08-30
EP1636226A1 (en) 2006-03-22

Similar Documents

Publication Publication Date Title
CL2007001882A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
CL2007001881A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
CL2007002169A1 (es) Compuestos derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso del compuesto para prevenir o tratar la inflamacion, trastornos urologicos, gastrointestina
CL2007003495A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer.
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
BRPI0915084A2 (pt) composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer
BR0112292A (pt) Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto
BRPI0612112A8 (pt) composto, composição farmacêutica, e, método de tratar doenças ou condições mediadas por ccr1.
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0717697A2 (pt) composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos
CR8642A (es) Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos
BRPI0613859B8 (pt) inibidores da comt, seus usos, e composição farmacêutica
CL2007003819A1 (es) Compuestos derivados de isoquinolina e isoquinolinona; composicion farmaceutica; y su uso para tratar y/o prevenir hipertension, retinopatia, glaucoma, fibrosis pulmonar, alzheimer, entre otras enfermedades.
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003832A1 (es) Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades.
CL2011002925A1 (es) Compuestos derivados de isoquinolin-1(2h)-ona, inhibidores selectivos de la actividad de poli (adp-ribosa) polimerasa parp-1; proceso para prepararlos; composicion farmaceutica; y su uso para tratar una enfermedad mediada por la proteina parp-1.
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
CL2007002578A1 (es) Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
GT200600081A (es) Derivados de acetilenno
CL2007002791A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica que comprende a estos compuestos; combinacion farmaceutica que comprende a estos compuestos; y su uso para tratar trastornos, enfermedades y afecciones seleccionadas de asma, broncoconstri
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
BRPI1007092A2 (pt) "derivados de hidroxamato, uso dos derivados de hidroxamato, composições farmacêuticas, método para prevenção ou tratamento de doença e método de produção de derivados de hidroxamato"
CL2007002272A1 (es) Compuestos derivados de n-metil-c-normorfinano; composicion farmaceutica; y uso para la reduccion de efectos secundarios del tratamiento de opioides tales como constipacion y nauseas, y para tratar trastornos mediados por la actividad de receptores o
BRPI0815696A2 (pt) composto derivados de benzimidazol, processo para a sua manufatura, composições farmacêuticas que os compreendem, metódo para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por agonistas de fxr e uso destes compostos.